Every material Form 8-K First Tracks Biotherapeutics, Inc. has filed with the SEC since October 15, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
First Tracks Biotherapeutics reported third-quarter 2026 results in an 8-K filing that attaches its earnings press release. The company reported a net loss of $31.4 million, or $0.88 per share, compared with $41.9 million, or $1.50 per share, in the same quarter of 2025, as research and development and general and administrative expenses both declined. Shareholders also received a business update that includes a $200 million private placement completed in October 2026, which the company said brings pro forma cash to $343 million.
Q3 2026 net loss was $31.4 million ($0.88 per share), versus $41.9 million ($1.50 per share) in Q3 2025.
Research and development expense was $23.8 million for Q3 2026, down from $33.3 million a year earlier.
Cash, cash equivalents and investments were $155.6 million at Sept. 30, 2026; pro forma cash is $343 million after the $200 million private placement.
For the nine months, the net loss was $115.2 million, compared with $131.5 million, while general and administrative expense rose to $37.1 million from $28.2 million.
First Tracks Biotherapeutics closed a private placement of 6,106,870 shares of its common stock on October 19, 2026, and entered into a registration rights agreement with the investors. The agreement requires the company to file or submit a resale registration statement with the SEC no later than 30 days after the closing date, which would allow those investors to resell the shares. The filing does not disclose the sale price or proceeds, so the financial effect on shareholders cannot be assessed from this document.
Closing date of the private placement: October 19, 2026
Aggregate of 6,106,870 common shares issued, par value $0.001 per share
Registration statement for investor resale due no later than 30 days after the closing date
Registration Rights Agreement filed as Exhibit 10.1, with some portions redacted and schedules omitted
First Tracks Biotherapeutics agreed on October 15, 2026 to sell 6,106,870 common shares at $32.75 each to institutional investors, for expected gross proceeds of about $200 million before placement fees and expenses. The deal is expected to close on October 19, 2026, and proceeds will fund general corporate purposes, including clinical development of ANB033. The new shares are unregistered and will be issued to investors who must be covered by a resale registration statement filed within 30 days after closing, so existing shareholders face dilution from the issuance and possible future resales.
Sale of 6,106,870 common shares at $32.75 per share, for about $200 million in gross proceeds before fees and expenses
Expected closing on October 19, 2026, subject to customary conditions
Placement agents are Leerink Partners, Piper Sandler, UBS Investment Bank and Wells Fargo Securities
Company had 35,909,814 common shares outstanding as of October 12, 2026; resale registration due within 30 days after closing
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every First Tracks Biotherapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →